Skip to main content
Fig. 4 | BMC Biotechnology

Fig. 4

From: Preparation of an anti-NEK2 monoclonal antibody and its application in liver cancer

Fig. 4

Effect of anti-NEK2 mAb on tumor cell proliferation by MTT assay. Anti-NEK2 mAb at final concentrations of 5 µg/mL, 25 µg/mL, 50 µg/mL and 100 µg/mL was added into hepatocellular carcinoma cells HepG2 and Hep3B for co-culture at 0 h, 24 h, 48 h and 72 h, respectively, and set up HepG2 and Hep3B cells without antibody as control. a The final concentration of anti-NEK2 mAb was 5 µg/mL. b The final concentration of anti-NEK2 mAb was 25 µg/mL. c The final concentration of anti-NEK2 mAb was 50 μg/mL (*P < 0.05). d The final concentration of anti-NEK2 mAb was 100 μg/mL (*p < 0.05, **p < 0.01)

Back to article page